Approval · Notice of Compliance 6018 · 2004

STRATTERA: Notice of Compliance 6018

Issued December 24, 2004

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 6018
Date: December 24, 2004
Company: Eli Lilly Canada IncToronto, Ontario, Canada
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: New Active Substance (NAS)
Therapeutic class: Selective norepinephrine reuptake inhibitor

Products in this notice

Brand	DIN	Status today
STRATTERA	02262800	Cancelled Post Market
STRATTERA	02262819	Cancelled Post Market
STRATTERA	02262827	Cancelled Post Market
STRATTERA	02262835	Cancelled Post Market
STRATTERA	02262843	Cancelled Post Market

Medicinal ingredients

ATOMOXETINE HYDROCHLORIDE 10 MG per CAP
ATOMOXETINE HYDROCHLORIDE 18 MG per CAP
ATOMOXETINE HYDROCHLORIDE 25 MG per CAP
ATOMOXETINE HYDROCHLORIDE 40 MG per CAP
ATOMOXETINE HYDROCHLORIDE 60 MG per CAP